Omalizumab as monotherapy for food allergy.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
27
3
2021
medline:
15
12
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
To familiarize the reader with the most recent insights in the use of Omalizumab (monoclonal anti-immunoglobulin E) monotherapy in the treatment of patients with severe food allergy. The current data from early stage clinical trials show that Omalizumab may be safe and effective by itself in providing desensitization to one or several foods without requiring allergen exposure. In the near future, advances in knowledge will guide the adoption and implementation of any new therapy for food allergy and allow the development of a personalized treatment tailored on the specific patient's profile.
Identifiants
pubmed: 33769312
doi: 10.1097/ACI.0000000000000744
pii: 00130832-202106000-00010
doi:
Substances chimiques
Allergens
0
Antibodies, Monoclonal
0
Omalizumab
2P471X1Z11
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-291Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Nwaru BI, Hickstein L, Panesar SS, et al. The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy 2014; 69:62–75.
de Silva D, Singh C, Muraro A, et al. Diagnosing, managing and preventing anaphylaxis: systematic review. Allergy 2020; doi: 10.1111/all.14580. Epub ahead of print.
doi: 10.1111/all.14580.
Gupta RS, Warren CM, Smith BMJ, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open 2019; 2:e185630.
Patel N, Herbert L, Green TD. The emotional, social, and financial burden of food allergies on children and their families. Allergy Asthma Proc 2017; 38:88–91.
Wai HM, Middelveld R, Thornqvist V, et al. Pediatric food allergy-related household costs are influenced by age, but not disease severity. World Allergy Organ J 2019; 12:100061.
Versluis A, Knulst AC, Kruizinga AG, et al. Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review. Clin Exp Allergy 2015; 45:347–367.
Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 2016; 137:1103–10 e11.
Arasi S, Mennini M, Valluzzi R, et al. Precision medicine in food allergy. Curr Opin Allergy Clin Immunol 2018; 18:438–443.
Hu J, Chen J, Ye L, et al. Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells. Clin Transl Allergy 2018; 8:27.
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73:799–815.
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy forIgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017; 72:1133–1147.
Cardet JC, Casale TB. New insights into the utility of omalizumab. J Allergy Clin Immunol 2019; 143:923–6 e1.
Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373–1377.
Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:1147–1154.
Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun 2020; 11:165.
Xolair (Omalizumab) [Online], European Medicines Agency. Available from https://www.ema.europa.eu/en/medicines/human/EPAR/xolair#product-information-section . Last access on the 3rd January 2021.
Xolair Prescribing Information [Online], Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103976s5235lbl.pdf#page=40 . Last access on the 3rd January 2021.
Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986–993.
Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309–10 e1.
Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012; 130:1123–9 e2.
Fiocchi A, Artesani MC, Riccardi C, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract 2019; 7:1901–9 e5.
Arasi S, Colucci C, Cafarotti A, et al. Impact of Omalizumab on severe food allergy in 54 Italian patients with concomitant asthma: 6-year-long experience Allergy: Special Issue: Abstracts from the European Academy of Allergy and Clinical Immunology Digital Congress LB-OAS1650; 75 (S109): 106 (oral communication) 2020; https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14505
doi: https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14505
https://clinicaltrials.gov/ct2/show/NCT03881696 . Last access on the 3rd January 2021.
Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients. J Allergy Clin Immunol 2021; 147:233–243.
Lupinek C, Derfler K, Lee S, et al. Extracorporeal IgE immunoadsorption in allergic asthma: safety and efficacy. EBioMedicine 2017; 17:119–133.
Dahdah L, Ceccarelli S, Amendola S, et al. IgE immunoadsorption knocks down the risk of food-related anaphylaxis. Pediatrics 2015; 136:e1617–e1620.
Kornmann O, Watz H, Fuhr R, et al. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulm Pharmacol Ther 2014; 28:149–153.
Brandstrom J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019; 49:1328–1341.
Arasi S, Nurmatov U, Turner PJ, et al. Consensus on DEfinition of Food Allergy SEverity (DEFASE): Protocol for a systematic review. World Allergy Organ J 2020; 13:100493.
https://www.gene.com/media/press-releases/14740/2018-08-12/fda-grants-breakthrough-therapy-designat . Last access on the 3rd January 2021.